This Ivy League Dropout Can Predict How You Might Die
Kian Sadeghi shares his journey, beginning with a personal tragedy that inspired the creation of Nucleus. He explains the decreasing cost and increasing value of genome sequencing and his decision to drop out of UPenn to focus on build a biotech company. Kian shares the challenges he faced and the strategies he used to raise $18 Million from investors such as Alexis Ohanian. He highlights the advantages of being a young founder and demystifies genome sequencing. The conversation explores the future of genome data, its integration with personal hardware, and the hurdles in building consumer trust. Kian also reflects on the role of PhDs, the long-term vision for Nucleus, the lessons learned from failures, and how he manages stress.
Key Points
- Understanding your genetic makeup through whole genome sequencing can help prevent and manage diseases by providing actionable insights into your health risks.
- Advancements in genomic technologies have drastically reduced the cost of sequencing, making it more accessible for people to have their entire genome analyzed.
- Building a successful biotech startup involves not only technical expertise but also perseverance, adaptability, and a strong focus on delivering value to the customer.
š¦ Follow the host: https://x.com/shamusmadan
š© Join The Dealroom: https://dealroompodcast.com/subscribe
Learn More About Nucleus Genomics: https://mynucleus.com/
Huge shout out to Savraj Singh for making this episode possible!
Chapters
| 0:00 | |
| 2:54 | |
| 6:10 | |
| 10:49 | |
| 14:57 | |
| 19:19 | |
| 23:13 | |
| 31:12 | |
| 33:29 | |
| 36:09 |
Transcript
Loading transcript...